Background: Peroxidation of low-density lipoprotein (LDL) plays an important role in the development of dyslipidemias associated with the progression of chronic renal disorders. We recently reported [J Lipid Res 2001;42:697, 2002;43:148644:716] that oxidized LDL (oxLDL) interacts with an endogenous plasma protein, ß 2 -glycoprotein I (ß 2 GPI), via specific ligands. In the present study, the prevalence and clinical significance of oxLDL/ß 2 GPI complexes were evaluated in patients with chronic renal disorders. Methods: Serum levels of oxLDL/ß 2 GPI complexes were measured by ELISA in patients with chronic renal disease and their association with clinical manifestations was assessed. Results: The serum levels of oxLDL/ß 2 GPI complexes were significantly higher in patients with chronic renal failure (CRF), chronic nephritis (CN) and diabetes mellitus than those in healthy individuals. The presence of complexes in patients with CN was significantly associated with high dietary protein and sodium chloride intake, but not with lipid metabolic parameters. Malondialdehyde-modified LDL was significantly associated with total cholesterol and LDL cholesterol in all patient groups, but did not correlate with renal function parameters. Conclusions: Serum oxLDL/ß 2 GPI complexes, generated by oxidative stress and associated with high dietary protein and salt intake, might be a novel risk factor and a diagnostic marker for the development of chronic renal diseases, especially IgA nephropathy.
Introduction
Experimental and clinical studies demonstrated an involvement of dyslipidemia in the progression of chronic renal disorders [1] and important role of oxidized LDL (oxLDL) in the pathogenesis of progressive glomerulosclerosis [2, 3] . oxLDL stimulates the production of the extracellular matrix protein and fibronectin by glomerular epithelial cells via the expression of transforming growth factor-ß, a major profibrotic growth factor [4] .
Several lines of evidence suggest an involvement of oxLDL in the pathogenesis of atherosclerosis [5] [6] [7] [8] [9] . The cellular uptake of oxLDL in association with the activation of monocyte derived macrophages and vascular smooth muscle cells leads to the formation and accumulation of foam cells in the atherosclerotic intima. Reactive oxygen species are known to mediate renal injuries [10] . Reactive oxygen species induce lipid peroxidation of LDL, resulting in the derivatization of lysine residues of apolipoprotein B (apoB) by lipid peroxide breakdown products such as malondialdehyde (MDA) [11] . Chemically modified LDL, such as MDA-modified LDL, acetylated LDL and Cu 2+ -oxLDL have been used as experimental models of denatured LDL to study the mechanisms of atherogenesis [12, 13] . Among these various chemically modified LDLs, Cu 2+ -oxLDL is physiologically reproducible, i.e., it seems to be closely related to LDL oxidized in vivo by cells and to LDL extracted from arterial atherosclerotic plaques [13] . Further, a previous clinical study indicated that Cu 2+ -oxLDL might be etiologically (or pathogenically) more relevant oxLDL compared to other chemically modified LDLs, such as MDA-LDL [14] .
The antiphospholipid syndrome (APS) is characterized by vascular (venous and/or arterial) thrombosis and pregnancy morbidity [15] . The prothrombotic state of APS is associated with the presence of antiphospholipid antibodies, such as anticardiolipin antibodies and/or lupus anticoagulants. It is now widely understood that the major autoantigen for anticardiolipin antibodies found in the sera of APS patients is ß 2 -glycoprotein I (ß 2 GPI) [16] [17] [18] [19] [20] . It has also been shown that ß 2 GPI specifically binds to Cu 2+ -oxLDL, not to other chemically modified LDLs, and that anti-ß 2 GPI autoantibodies bind to oxLDL/ ß 2 GPI complexes [21] [22] [23] [24] . Based on these findings, we established a novel sandwich ELISA system for the detection of serum oxLDL/ß 2 GPI complexes. A monoclonal anti-ß 2 GPI antibody (WB-CAL-1), derived from a NZW ! BXSB F 1 mouse, a murine model for APS, was used as the capture antibody, and an anti-apoB100 antibody to determine the presence of LDL. With this system, we have also shown that the complexes likely acting as autoantigens were closely associated with autoimmunemediated atherogenesis [24] . More recently, we have demonstrated that oxLDL binds in vivo to endogenous ß 2 GPI, and that these complexes can be found in the bloodstream of patients with various chronic diseases, such as systemic lupus erythematosus (SLE) and APS [24] [25] [26] .
Because oxLDL formed in the bloodstream is rapidly removed from the circulation by non-parenchymal liver cells [13] , the resulting low levels of plasma oxLDL might be difficult to measure. However, our in vitro experiments showed that oxLDL quickly interacts with ß 2 GPI via specific ligands, generated by Cu 2+ oxidation, and that the negative charge of oxLDL is neutralized by the complex formed. Such electrostatically 'neutral' oxLDL/ ß 2 GPI complexes could escape from the 'scavenger' cells.
In the present study, we measured serum levels of oxLDL/ß 2 GPI complexes of patients with various chronic renal diseases, and evaluated their association with clinical manifestations. We also analyzed the correlation between the oxLDL/ß 2 GPI complex levels and clinical parameters to further understand the association of oxLDL/ ß 2 GPI complexes with the progression of renal disorders.
Materials and Methods

Subjects
A total of 140 Japanese patients examined and treated in the Okayama University Hospital (Okayama, Japan) were included in the present study. The patient population consisted of 78 chronic nephritis (CN) patients without severe renal function impairment, 32 chronic renal failure (CRF) patients, and 30 diabetes mellitus (DM) patients. The 78 CN and 32 CRF patients had a male-to-female ratio of 60:50 and a mean age of 49.0 years. CN was diagnosed and classified based on clinical, laboratory and histopathological findings obtained by renal biopsies. Patients with SLE and those positive for hepatitis B or C virus antigen were excluded from the study. Patients with overt proteinuria and/or renal dysfunction were excluded from the DM group in the present study. Patients were classified as having CRF when serum creatinine concentration was permanently higher than 2.0 mg/dl. Clinical records were carefully reviewed retrospectively (described in viewed at the time of sample collection. Twenty-nine age-matched healthy blood donors were used as controls. Informed consent was given to all subjects, and the study was approved by the Institutional Ethical Review Board of Okayama University Hospital. All serum samples were stored at -20°C until use.
Monoclonal Antibodies
A murine anti-ß 2 GPI antibody WB-CAL-1 (IgG2a, Î), was derived from a NZW ! BXSB F 1 (WBF 1 ) male mouse, an animal model of APS [27] . WB-CAL-1 binds only to ß 2 GPI complexed with oxLDL but not to free form of ß 2 GPI (i.e., ß 2 GPI in solution) [20, 27, 28] . An IgG monoclonal anti-apoB100 antibody (1D2) was obtained from Yamasa Corp. (Choshi, Japan). F(ab) 2 fragment of 1D2 antibody was prepared by digestion with pepsin.
Purification of Human ß 2 GPI ß 2 GPI was purified from normal human plasma as described previously with slight modification [19] . Briefly, pooled plasma from healthy subjects was chromatographed on a cardiolipin-polyacrylamide gel column, DEAE-cellulose column, and anti-ß 2 GPI affinity column. To remove any contamination by IgGs, the ß 2 GPI-rich fraction was further passed through a protein A-Sepharose column. The final ß 2 GPI fraction was delipidated by extensive washing with nbutanol.
Preparation of oxLDL
Plasma LDL (1.019 ! d ! 1.063) was isolated by ultracentrifugation from fresh normal human plasma, as described [29] . LDL (100 Ìg protein/ml) was oxidized by incubating with 5 ÌM CuSO 4 for 8 h at 37°C. To terminate the oxidation, 1 mM EDTA was added and oxidized sample was dialyzed extensively against PBS containing 1 mM EDTA. Protein concentration was determined using the BCA protein assay reagent (Pierce Chemical Co., Rockford, Ill., USA). An aliquot was taken to determine thiobarbituric acid reactive substance value [30] , and for use in agarose gel electrophoresis.
ELISA for oxLDL/ß 2 GPI Complexes
Monoclonal antibody against complexed ß 2 GPI (WB-CAL-1) was coated onto a 96-well microtiter plate (Immulon 2HB, Dynex Technologies, Inc., Chantilly, Va., USA) by incubating 50 Ìl/well of 5 Ìg/ ml of WB-CAL-1 in PBS, pH 7.4 (PBS), overnight at 2-4°C. The plate was blocked with PBS containing 1% skim milk (PBS-SM) for 1 h. 50 Ìl of 50 Ìg/ml of human ß 2 GPI in PBS-SM were added to each well, followed by 50 Ìl of the serum samples diluted at 1:50 in PBS-SM, and incubated for 1 h at room temperature. The wells were washed 3 times with PBS containing 0.05% Tween 20 between each step. Biotinylated 1D2 (anti-human apoB100) antibody diluted in PBS-SM was added to the wells and incubated for 1 h at room temperature, followed by horseradish peroxidase-streptavidin. Color was developed with o-phenylenediamine and H 2 O 2 and the reaction was stopped with 2 N sulfuric acid. Optical density (OD) was measured at 490 nm. Serum oxLDL levels (expressed as units/ml) were calculated against a reference curve built with 2-fold serial dilutions of the standard complexes. A normal cut-off value for the assay was established at 1.0 U/ml by testing 29 samples from healthy blood donors (mean + SD). The ELISA system is not affected by endogenous serum ß 2 GPI (at serum concentration of approx. 200 Ìg/ml) due to nonreactivity of WB-CAL-1 to free form of ß 2 GPI [20, 27, 28] . Schematic illustration of the ELISA system used in the present study to determine serum oxLDL/ß 2 GPI complexes. oxLDL/ ß 2 GPI complexes captured by solid-phase WB-CAL-1 antibody (Ab) were detected with biotinylated anti-apoB100 antibody and HRPavidin. The system may improve oxLDL detection by eliminating the possible interference from ß 2 GPI binding to oxLDL in conventional assay systems. 
Microtiter plate
Other Clinical Parameters Total cholesterol (TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), serum creatinine (sCr), 24-hour creatinine clearance (CCr), and urinary protein excretion (U-Pro), were measured by routine laboratory methods. MDA-LDL was kindly measured by a sandwich ELISA by SRL, Inc., Hachioji, Japan. Dietary protein intake and sodium chloride intake were calculated from U-Pro and urinary sodium excretion.
Statistical Analysis
All values are expressed as mean B SE. Statistical analysis was performed by StatView software (Abacus Concepts, Berkeley, Calif., USA). The Fisher's exact test was used to compare the appearance of oxLDL and clinical parameters. The Mann-Whitney U-test was used to assess possible correlation between the oxLDL/ß 2 GPI complex levels and occurrence of renal diseases or clinical manifestations. Correlation between two variables was evaluated by the Pearsons' correlation test. A level of p ! 0.05 was considered statistically significant.
Results
We have reported that oxLDL is predominantly circulating as stable and non-dissociable complexes (i.e., covalently formed) with ß 2 GPI in bloodstream of patients with SLE and APS [24] . In most recent our studies, such stable oxLDL/ß 2 GPI complexes were detected also in sera of patients with DM and CN (unpubl. data). We established an ELISA system to measure oxLDL/ß 2 GPI complexes and not only stable and dissociable but also electrostatic oxLDL complexes with ß 2 GPI, which might be present in Kasahara/Kobayashi/Maeshima/Yamasaki/ Yasuda/Matsuura/Makino serum samples, can also be detected in ELISA when exogenous ß 2 GPI is present. As shown in figure 1, in the ELISA, oxLDL/ß 2 GPI complexes captured on a WB-CAL-1-adsorbed plate were detected by the probe antibody (anti-apoB100, 1D2) because WB-CAL-1 binds only to ß 2 GPI complexed with oxLDL but not to the free form of ß 2 GPI (i.e., ß 2 GPI in solution) [20, 27, 28] . Basic profiles on the ELISA are indicated in figure 2. When Cu 2+ -oxLDL was incubated in an assay well together with 25 Ìg/ml (final concentration) of exogenous ß 2 GPI, oxLDL immediately formed electrostatic complexes with ß 2 GPI but native LDL did not ( fig. 2a) . Formation of electrostatic oxLDL/ß 2 GPI complexes are dose dependent of either oxLDL or ß 2 GPI (fig. 2b) . However, the measurement of the complexes in serum samples was not affected by exogenous ß 2 GPI (at a final concentration of 25 Ìg/ml in an assay well) ( fig. 2c ). Dilution test of serum samples indicated that satisfactory quantitative determination was provided by the ELISA (fig. 2d ). Mean recovery of 103.4% (range 91.4-112.7%, n = 3) using Cu 2+ -oxLDL was also obtained in a recovery test (details not shown). Thus, oxLDL/ß 2 GPI complexes in serum samples can be detected in the ELISA without any influence of endogenous (serum-derived) or exgenous ß 2 GPI.
In case of the conventional oxLDL ELISA, antioxLDL antibodies were coated on a microplate, and captured oxLDL detected with probed anti-apoB100 antibody. Since ß 2 GPI is abundantly present in human serum and readily binds to oxLDL, it is possible that the epitope on oxLDL is masked by ß 2 GPI binding, producing falsenegative results in this assay. As previously described, in our assay system, the WB-CAL-1 capturing antibody is specific for ß 2 GPI complexed with oxLDL, and does not react with free ß 2 GPI in solution. Thus, oxLDL/ß 2 GPI complexes in serum samples are captured by the solidphase antibody, and further detected by a probed antiapoB100 antibody. This system eliminates the possible masking effect by ß 2 GPI and results provide accurate detection of total amount of oxLDL, i.e., complexed and free oxLDL in the sera, as oxLDL/ß 2 GPI complexes. Basic profiles of ELISA for oxLDL/ ß 2 GPI complexes. a Specific detection of Cu 2+ -oxLDL as electrostatic complexes with ß 2 GPI in ELISA. Cu 2+ -oxLDL and native LDL were incubated in an assay well in the presence of exogenous ß 2 GPI (at final concentration of 25 Ìg/ml). b Dose dependency of ß 2 GPI on free Cu 2+ -oxLDL determination (to be form electrostatic oxLDL/ß 2 GPI complexes) in the ELISA. OD at 490 nm was indicated under various concentrations (at final concentration of 0, 0.16, and 2.5 Ìg/ml of exogenous ß 2 GPI. c Influence of exogenous ß 2 GPI (at final concentration of 25 Ìg/ ml in System I and 0 Ìg/ml in System II) on oxLDL/ß 2 GPI values (OD) obtained in the ELISA. d Dilution test of four serum samples in the ELISA. Serum samples were serially diluted (at 1:1-16) with PBS-SM. The diluted samples were then diluted at 1:50 (finally 1:100-fold diluted in a well) to apply for the ELISA. The study patients, according to their diagnoses, are presented in table 1. Serum levels of oxLDL/ß 2 GPI complexes were determined in all 29 normal subjects, 110 patients with renal disease and 30 patients with DM. As shown in figure 3 , the serum levels of oxLDL/ß 2 GPI complexes in all groups of chronic renal diseases and DM were significantly higher than in normal subjects; 0.56 B 0.08 units/ml in normals, 1.16 B 0.12 units/ml in CN (p = 0.004 by Mann-Whitney U-test), 1.08 B 0.07 units/ml (p ! 0.0001) in CRF, and 3.02 B 0.23 units/ml (p ! 0.0001) in DM. As previously reported [24] , there was also a significant difference between the serum complex levels in patients with SLE and/or APS and those in normal subjects, as well.
In the subset of CN patients with immunoglobulin A nephropathy (IgAN), oxLDL/ß 2 GPI complex levels (1.34 B 0.18 units/ml) were also significantly higher than in normal subjects (p ! 0.0004, fig. 4 ). However, patients with minimal change nephrotic syndrome (MCNS, 0.79 B 0.27 units/ml), membranous nephropathy (MN, 0.68 B 0.45 units/ml), or focal glomerulosclerosis (FGS, 0.82 B 0.45 units/ml) had higher levels than normal subjects, but these differences did not reach statistical significance, Fig. 3 . Serum oxLDL/ß 2 GPI complex levels in patients with various chronic diseases. Serum levels of oxLDL/ß 2 GPI complexes were measured by a sandwich ELISA as described in Materials and Methods. oxLDL/ß 2 GPI levels are expressed in arbitrary units (units/ml). A sample was considered positive when its complex level (units/ml) was higher than the mean +1 SD calculated from 29 healthy volunteers (cut-off value). The number of patients and mean values for each group are shown at the bottom and next to the horizontal lines. possibly due to the small patient number in these disease populations. Although the numbers of patients were probably too small to achieve statistical significance, the patients diagnosed to have membranoproliferative glomerulonephritis (MPGN, 2.34 B 0.46 units/ml) or non-IgA nephropathy (1.80 B 0.59 units/ml) exhibited much elevated complex levels. The levels of the complexes in patients with crescentic glomerulonephritis (0.98 B 0.25 units/ml) or interstitial nephritis (0.85 B 0.53 units/ml) were not elevated. In CN patients, the serum oxLDL/ß 2 GPI complex levels were not significantly associated with increased TC (1220 mg/dl), LDL-C (1140 mg/dl) or reduction of HDL-C levels (!50 mg/dl), and loss of renal function (24-hour CCr !70 ml/min) or proteinuria (11 g/day). In contrast, elevated complex levels were significantly associated with excessive intake of dietary proteins (11 g/kg body weight/ day; p = 0.005) and excessive intake of sodium chloride (17 g/day; p = 0.007) in patients with CN (table 2). In patients with CRF, the complex levels did not correlate with any serum lipid parameter, creatinine, and urinary protein content (data not shown). Similarly, serum complex levels of DM patients did not correlate with TC, TG, HDL-C, LDL-C, HbA 1C or microalbuminuria (data not shown).
Finally, we measured the serum levels of MDA-LDL, commonly regarded as an atherogenic modified LDL, and CN, fig. 6 ). MDA-LDL significantly correlated with TC (r 2 = 0.60, p ! 0.0001 in CRF, r 2 = 0.37, p ! 0.0001 in CN), and with LDL-C (r 2 = 0.36, p ! 0.005 in CRF, r 2 = 0.27, p ! 0.001 in CN). However, there was no association between MDA-LDL levels and parameters of renal function (data not shown).
Discussion
Previous studies have demonstrated that oxLDL induces various cellular responses such as vasoconstriction [31] , overexpression of adhesion molecules [32] and proliferation of macrophages [33] . The role of lipids in progressive renal disorders and the similarity of focal segmental glomerulosclerosis to atherosclerosis have been demonstrated [2, 34, 35] . Atherogenic lipoproteins accumulate in the arterial wall, as well as in glomeruli, and accelerate vascular and glomerular injuries [36] . In some experimental glomerulonephritis models and in human renal biopsy specimens, the deposition of oxLDL was detected within the glomeruli [37, 38] . Atherogenic lipoproteins induce the formation of oxygen radicals not only in arteries, but also in the glomeruli, causing proliferation of mesangial cells and inhibition of nitric oxide-mediated vasodilatation [39] . Additionally, oxLDL and Lp(a) stimulate juxtaglomerular cells to release renin by a mechanism involving oxygen-derived radicals, contributing to renin-dependent hypertension in renoparenchymatous renal diseases [40] .
In the present study, we measured serum levels of oxLDL/ß 2 GPI complexes in patients with renal disorders. oxLDL has been implicated in the pathogenesis of atherosclerosis [5] and previous studies suggested that immune mechanisms are involved in atherogenesis [41] . We previously demonstrated that oxLDL formed complexes with ß 2 GPI, which were subsequently targeted by anti-ß 2 GPI autoantibodies, considered the pathogenic autoantibodies in patients with APS [21] [22] [23] [24] . Based on these findings, we established a sandwich ELISA for detecting oxLDL/ß 2 GPI complexes in serum samples. The advantage of our system in comparison with the previous oxLDL assays is that it eliminates the interference created by ß 2 GPI binding to oxLDL. oxLDL assays regularly utilize an antibody against oxidized lipoproteins to capture circulating oxLDL. It is possible that epitopes on oxLDL recognized by anti-oxLDL antibodies are masked by the attachment of endogenous ß 2 GPI resulting in false-negative results.
oxLDL/ß 2 GPI complexes in the subgroups of patients with CRF or DM were significantly higher than in normal subjects. In general, patients with DM and CRF are thought to be exposed to greater amounts of oxidative stress. The fact that elevated oxLDL/ß 2 GPI levels were observed in these disease entities is consistent with the hyperoxidative nature of these disorders. A recent study employing a conventional oxLDL ELISA showed increased levels of oxLDL in patients with end-stage renal disease (ESRD) undergoing hemodialysis [42] , results similar to our findings. Interestingly, our results demonstrated that CN patients without deterioration of renal function exhibited elevated levels of oxLDL/ß 2 GPI complexes as compared to healthy control. A previous study using a conventional oxLDL ELISA reported high serum oxLDL levels in patients with mild CRF as compared to control subjects [43] . However, patients with severe CRF or ESRD patients on hemodialysis exhibited higher levels of oxLDL than patients with mild CRF [43] . We found that oxLDL/ß 2 GPI complex levels did not significantly differ between patients with CN and CRF, but tended to be higher in the CN group. The discrepancy between our study and the previous study [43] may be attributed to different detection methods. Our findings demonstrate a significant elevation of serum oxLDL/ß 2 GPI complexes in patients with IgAN, but not in other chronic renal disorders. A recent report from another group demonstrated the presence of circulating anti-oxLDL antibodies in patients with chronic glomerulonephritis [44] . They also found that patients with IgAN exhibited particularly high serum levels of anti-oxLDL antibodies. Although they did not measure oxLDL/ß 2 GPI complexes directly, the elevated levels of anti-oxLDL antibodies might be associated with higher levels of oxLDL/ß 2 GPI complexes in patients with IgAN. The precise mechanism(s) of the induction of oxLDL/ß 2 GPI complexes in chronic renal diseases, especially in patients with IgAN, are yet to be determined. Among 37 patients with IgAN, only 7 patients exhibited daily urinary protein excretion (24 h) above 1 g. Regarding serum creatinine, there were 28 patients in the range of 0-1 mg/dl, and 9 patients in the range of 1-1.7 mg/dl. Therefore, most of patients were considered to exhibit less Kasahara/Kobayashi/Maeshima/Yamasaki/ Yasuda/Matsuura/Makino active and chronic histologicalchanges. Although 37 patients were initially diagnosed as IgAN by renal biopsies and some patients had previously been treated with glucocorticoids, most of patients were under stable (inactive) condition in the present study period. We speculate that systemic up-regulation of inflammatory factors may induce lipid peroxidation in these disorders or that they may influence on the synthesis of local factors in kidney. This may subsequently lead to the generation of oxLDL and formation of oxLDL/ß 2 GPI complexes. In spite of the small number of patients studied, serum oxLDL/ß 2 GPI complex levels of patients with MPGN or non-IgA nephropathy were elevated, suggesting an association between increased serum oxLDL/ß 2 GPI complex levels with mesangial cell proliferation. However, larger populations of these disease categories are required for appropriate interpretation.
Increased serum oxLDL/ß 2 GPI complexes did not correlate with lipid parameters, i.e., TC, LDL-C, HDL-C or TG in CN, CRF or DM patients. Parameters of renal dysfunction (serum creatinine, 24-hour CCr) also did not correlate with increased serum levels of oxLDL in patients with CN, CRF or DM. A recent study detecting the levels of serum anti-oxLDL antibodies also failed to observe a significant correlation with laboratory findings reflecting renal diseases [44] . Another study on DM patients, using a conventional ELISA, showed a significant increase of serum oxLDL in patients with overt proteinuria (macroalbuminuria), but not in patients with microalbuminuria or normoalbuminuria [45] . Our results, however, do not preclude the possibility that elevated oxLDL/ß 2 GPI complex levels detected in our novel ELISA may reflect the deterioration of renal function, thus serving as a potential prognostic marker for patients with IgAN. Follow-up analysis to examine oxLDL/ß 2 GPI complex levels after 5-10 years may clarify the prognostic potential of oxLDL/ß 2 GPI complexes in the cohort of patients with IgAN. In CN patients, the range of oxLDL/ß 2 GPI complexes level was widely distributed from 0 to 18.5 U/ml. In contrast, among CRF and DM patients, there were no subjects with undetectable oxLDL/ß 2 GPI complexes. Because patients with DM and CRF are constantly exposed to an oxidative state due to hyperglycemia, uremia and/or hypertension, oxLDL/ß 2 GPI complex levels may be continuously elevated.
In CN patients, elevated serum oxLDL/ß 2 GPI complex level significantly correlated with increased dietary protein and sodium intake. CN patients who exhibit proteinuria (11 g/day), hypertension and loss of renal function, are commonly instructed in our facility to follow diet restriction with low protein (0.8 g/kg body weight/day) and low sodium intake (7 g/day). Interestingly, serum levels of oxLDL/ß 2 GPI complexes of CN patients who failed to follow dietary restriction, tended to be higher than those of patients under preserved dietary restriction. We speculate that dietary overload of protein and salt may contribute to increased oxLDL/ß 2 GPI complex levels in patients with CN, and that this mechanism may be, at least in part, involved in the progressive deterioration of renal function with higher protein and salt intake.
Next, we measured serum levels of MDA-LDL, generally regarded as the atherogenic lipoprotein, and assessed its correlation with oxLDL/ß 2 GPI complexes in patients with CRF and CN. In patients with CN and CRF, serum levels of MDA-LDL were significantly higher than in healthy subjects, and exhibited a positive correlation with T-C and LDL-C. However, complex levels did not show a significant correlation with T-C or LDL-C. Among various chemically modified LDLs, i.e. MDA-modified oxLDL, acetylated oxLDL, and Cu 2+ -mediated oxLDL, only Cu 2+ -mediated oxLDL closely resembles LDL oxidized by cells or LDL extracted from arterial atherosclerotic plaques [12] . In the previous clinical study, Cu 2+ -mediated oxLDL was considered to be similar to physiological oxLDL compared with other chemically modified LDLs, such as MDA-LDL [14] . Our results suggest an increased clinical significance of oxLDL in contrast to MDA-LDL in patients with chronic renal disorders. In patients with CN, mild oxidation of LDL, not as severe as in MDA-LDL, may reflect a mild renal dysfunction prior to severe loss of renal function.
In summary, we established an ELISA for detecting circulating oxLDL/ß 2 GPI complexes that is not affected by the presence of ß 2 GPI, and observed a significant increase of oxLDL/ß 2 GPI complexes in patients with chronic renal diseases, especially in those with IgAN. The serum levels of oxLDL/ß 2 GPI complexes correlated with a higher dietary protein or salt intake in the group of CN patients, suggesting that dietary restriction may suppress lipid peroxidation, which could be an explanation for its beneficial effect on the progression of chronic renal disorders. Further analyses including follow-up of oxLDL/ ß 2 GPI complex levels and clinical parameters of renal diseases shall clarify the meaning of oxLDL/ß 2 GPI complexes as a potential prognostic marker of chronic renal disease.
